Literature DB >> 32748167

Long-pulsed 1064-nm and 755-nm lasers for C1 leg veins on skin type IV patients: a side-by-side comparison.

Huyen Tran Ngoc Nguyen1,2, Al-Niaimi Firas3, Trung The Van4.   

Abstract

Long-pulsed 1064-nm (LP1064) and 755-nm (LP755) lasers have been demonstrated as effective treatments for leg veins. However, few studies of these treatments on Asian skin type as well as direct comparison between two methods were reported. The aim of this study was to compare the clinical efficacy and safety of LP1064 with LP755 in the treatment of C1 leg veins on skin type IV patients. Patients with symmetric matched areas C1 leg veins were treated with single session of LP1064 for the right and LP755 for the left. Treated areas of every patient were divided into matrices of 2 × 2 cm squares. Vessels in the highest density squares were subjected to evaluation. Spot sizes were 5 mm fixed. Pulse durations and fluences were according to vessel diameters and endpoints, respectively. The clearances were evaluated at 1 and 3 months post treatment. Side effects were recorded immediately, 10 min, 24 h, and 1 and 3 months after treatment. Twenty-two patients were enrolled with total 96 vessels from 22 selected squares in the right and 106 vessels from 22 selected squares in the left. At 1-month follow-up, the clearances of LP1064 and LP755 were not significantly different (71.87% and 71.69%, respectively; p = 0.99). At 3-month follow-up, the efficacies were constant and no recurrence occurred. Pain levels of both methods were moderate and significantly lower in LP755. These findings suggest that LP1064 and LP755 laser treatments were comparatively effective and safe for C1 leg veins of skin type IV patients.

Entities:  

Keywords:  Clinical trial; Leg veins; Long-pulsed 1064-nm Nd:YAG laser; Long-pulsed 755-nm alexandrite laser; Reticular veins; Telangiectasia

Mesh:

Year:  2020        PMID: 32748167     DOI: 10.1007/s10103-020-03116-w

Source DB:  PubMed          Journal:  Lasers Med Sci        ISSN: 0268-8921            Impact factor:   3.161


  24 in total

Review 1.  Laser leg vein treatment: a brief overview.

Authors:  Victor Ross; Yacov Domankevitz
Journal:  J Cosmet Laser Ther       Date:  2003-12       Impact factor: 2.247

2.  Laser therapy of spider leg veins.

Authors:  U Wollina; W-D Schmidt; J Hercogova; D Fassler
Journal:  J Cosmet Dermatol       Date:  2003-07       Impact factor: 2.696

Review 3.  Clinical, aetiological, anatomical and pathological classification (CEAP): gold standard and limits.

Authors:  E Rabe; F Pannier
Journal:  Phlebology       Date:  2012-03       Impact factor: 1.740

Review 4.  Laser therapy for leg veins.

Authors:  Joy H Kunishige; Leonard H Goldberg; Paul M Friedman
Journal:  Clin Dermatol       Date:  2007 Sep-Oct       Impact factor: 3.541

5.  Complications of sclerotherapy.

Authors:  Girish S Munavalli; Robert A Weiss
Journal:  Semin Cutan Med Surg       Date:  2007-03

Review 6.  Complications of sclerotherapy: an update.

Authors:  Jean-Jérôme Guex
Journal:  Dermatol Surg       Date:  2010-06       Impact factor: 3.398

7.  European guidelines for sclerotherapy in chronic venous disorders.

Authors:  E Rabe; F X Breu; A Cavezzi; P Coleridge Smith; A Frullini; J L Gillet; J J Guex; C Hamel-Desnos; P Kern; B Partsch; A A Ramelet; L Tessari; F Pannier
Journal:  Phlebology       Date:  2013-05-03       Impact factor: 1.740

8.  Pulsed alexandrite laser for the treatment of leg telangiectasia and reticular veins.

Authors:  A N Kauvar; W W Lou
Journal:  Arch Dermatol       Date:  2000-11

9.  Lasers for vascular lesions: standard guidelines of care.

Authors:  C R Srinivas; M Kumaresan
Journal:  Indian J Dermatol Venereol Leprol       Date:  2011 May-Jun       Impact factor: 2.545

Review 10.  Treating vascular lesions.

Authors:  Susanne Astner; R Rox Anderson
Journal:  Dermatol Ther       Date:  2005 May-Jun       Impact factor: 2.851

View more
  1 in total

Review 1.  Treatment for telangiectasias and reticular veins.

Authors:  Luis Cu Nakano; Daniel G Cacione; Jose Cc Baptista-Silva; Ronald Lg Flumignan
Journal:  Cochrane Database Syst Rev       Date:  2021-10-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.